Cancer treatment has improved over the past two decades by leveraging the body's immune system or immunotherapy to combat the disease. A study published in the journal Molecular Cancer describes promising results in cancer treatment using a combination of immunotherapy and Danish technology.
Researchers from Odense University Hospital and the University of Southern Denmark have collaborated with a Danish biotech company, CytoVac, to develop a novel approach for optimizing cancer treatment effectiveness. The strategy utilized in the study the isolation and maturing T-cells (a type of white blood cell involved with immunity) from a patient's blood in a laboratory and reintroducing them back into their body. This approach markedly helps to prevent the spread of cancer cells if the patient also receives drugs that prevent cancer cells from inhibiting T-cell activity. This therapy has yielded positive results in initial animal studies focusing on triple-negative breast cancer, a form of the disease that has limited treatment options. While further research is needed to validate these findings in human trials, the potential for this combined treatment to improve outcomes in various types of cancer offers hope for future advancements in oncology.
0 Comments
Leave a Reply. |
AuthorNatasha Tiffany, MD, is a physician, educator, and research scientist currently working in Oregon. A Partner and Physician in a private practice located in the state’s capital city of Salem, Dr. Tiffany teaches at her alma mater, Oregon Health & Science University, where she is an Affiliate Assistant Professor in the Hematology and Medical Oncology Division. Archives
October 2019
Categories
All
|